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Abstract
Background: The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled
Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human
Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug.
Methods: Eight hundred forty-eight (848) IVF patients classified as expected “poor” or “normal” responders according
to antral follicle count (AFC) and basal (day 3) FSH were treated with rFSH + rLH (2:1 ratio, n = 398, Group A) or
hMG (n = 450, Group B). Data were collected under real-life practice circumstances and the pregnancy rate with fresh
embryos was calculated by stratifying patients according to the number of retrieved oocytes (1–2, 3–4, 5–6, 7–8, >8).
Results: Overall, the pregnancy rate in both groups progressively improved according to the number of oocytes
retrieved. When comparing patients within the same subgroup of oocyte yield, Group A and B showed a comparable
outcome up to the reported highest yield (>8). When more than 8 oocytes were available, Group A had a significantly
better pregnancy rate outcome. Patients’ characteristics did not significantly differ between the two groups and the
better outcome in the best responding patients in Group A was confirmed by a multivariable logistic regression analysis,
that showed that both the use of rFSH + rLH and the total number of retrieved oocytes increased the probability of
pregnancy with odd ratio (OR) of 1.628 and 1.083, respectively.
Conclusions: When comparing patients with the same number of retrieved oocytes under real-life circumstances, the
association of rFSH + rLH results in a significantly higher pregnancy rate than hMG when more than 8 oocytes are
retrieved. The reason(s) for this are unknown, but a more favorable effect on oocyte quality and/or endometrial
receptivity could be involved.
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Background
To date, no confirmed evidence is yet available as to
which gonadotropin (or gonadotropin association) is more
effective when performing controlled ovarian stimulation
(COS) in human in vitro fertilization (IVF). The hetero-
geneity of infertility condition and of patients’ profile,
together with the availability of several medications that
can be combined in various different regimens, lead to
the need of individualizing COS regimen as a specific
protocol could be effective on one definite patient and
not in another [1].
Randomized Controlled Trials (RCTs) are recognized
as the “gold standard” for assessing the efficacy of a
given therapeutic regimen, but they cannot provide a
true indication of effectiveness as they operate in an
idealized environment and measure efficacy in limited,
standardized populations. Moreover, both patients and
physicians in a clinical trial may behave differently
simply because they know to be in a trial and being
observed (the so-called Hawthorne effect) [2]. As a
consequence, the conclusions of RCTs are not always a
useful aid for decision-making, as assessing the value of
a drug (or of a treatment protocol) requires the compre-
hension of its impact on current management in a prac-
tical real-life setting [3]. Real-life data may be obtained
from the retrospective evaluation of a database, and pro-
vide additional insights coming from a more realistic
clinical environment; internationally, this additional ef-
fectiveness assessment is increasingly used in the devel-
opment of evidence-based documentation of a treatment
value, particularly when a medical treatment is sub-
mitted to evaluation for pricing and reimbursement
decision [4].
In the last decades, a bulk of published data compar-
ing human Menopausal Gonadotropin (hMG) vs recom-
binant Follicle Stimulating Hormone (rFSH) in human
IVF have been published, but they have not been able
to demonstrate any significant difference in live birth
rate [5, 6], although showing a higher oocyte yield with
the recombinant molecule [6, 7]. After recombinant
Luteinizing Hormone (rLH) was made available, both
retrospective [8, 9] and prospective [10–14] studies re-
ported that rLH addition to rFSH was unable to increase
the number of oocytes and/or improve the outcome vs.
rFSH alone. Differently, however, other studies showed
increased pregnancy and implantation rates in some
subset of patients receiving rLH in addition to rFSH
[15, 16], and a recent, large meta-analysis suggested that
rLH supplementation might result in a higher clinical
pregnancy rate in the overall population, and particularly
in the poorly responding patients [17]. Rather surpris-
ingly, no large studies comparing hMG with rFSH + rLH
have been performed, and the available data are still
scarce and inconclusive.
The aim of the present study was to compare, applying
the real-life data approach on a routine clinical activity,
the effectiveness of COS protocols with rFSH + rLH vs
hMG in a well-defined subset of IVF patients. In order
to exclude the interference of a different oocyte yield, we
evaluated the pregnancy rate obtained after patients’
stratification in subgroups according to the number of
retrieved oocytes.
Methods
Patients
The study was authorized by the local Ethical Committee
and was registered at Clinical Trials.gov with number
NCT02322398.
Data were collected from the clinical charts of our IVF
Unit database, including all patients undergoing IVF in
the period between 2010–2014, in which the Italian rules
on assisted reproduction allowed the use of all mature
oocytes and the freezing of surplus embryos. IVF patients
were classified according to basal antral follicle count
(AFC) and basal (day 3) FSH levels as “expected poor re-
sponders” (ePR; AFC ≤ 7, FSH ≥ 12 U/l) “expected normal
responders” (eNR; AFC 8–15, FSH 8.1–11.9 U/l), or
“expected high responders” (eHR; AFC ≥ 16, FSH ≤ 8 U/l).
Among 3,416 cases recorded, approximately two thirds
matched the criteria defined as ePR or eNR, and 848 of
them received a COS with LH activity-containing medica-
tions, whereas the others were stimulated using FSH alone.
In detail, 398 patients (Group A) were stimulated with
rFSH + rLH, whereas 450 patients (Group B) were treated
with hMG. The clinical characteristics of enrolled patients
appear in Table 1.
IVF treatment protocols
Patients in Group A (n = 398) received either a starting
dose of 150–300 IU/d recombinant FSH (rFSH; Gonal
F®; Merck-Serono, Germany) plus 75–150 IU/d recom-
binant LH (rLH; Luveris®; Merck-Serono, Germany) in
2:1 ratio, or 150–300 IU/d rFSH + rLH/2:1 (Pergoveris®,
Merck-Serono, Germany). On day 6–7 of ovarian stimu-
lation, the gonadotropin dose was adapted according to
the ovarian response, always maintaining a rFSH:rLH/
2:1 ratio. Patients in Group B (n = 450) received 150–
300 IU/d hMG (Meropur®, Ferring Pharmaceuticals,
Germany or Merional®, IBSA, Switzerland). On day 6–7
of ovarian stimulation, the hMG dose was eventually
adjusted according to the ovarian response.
Both medications were administered within a “long”
protocol with GnRH-agonists or a “short” protocol with
GnRH-antagonists. In the absence of any pre-fixed cri-
teria, the COS regimen (type of protocol and type of
medication) was decided and prescribed by different
physicians of the Unit according to their own clinical ex-
perience, as per real-life clinical practice. As a common
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background, the choice of the starting gonadotropin
dose was based on age, body mass index (BMI), AFC,
basal FSH as well as on the response to previous COS.
The classical “long” protocol was performed adminis-
tering the GnRH-agonist buserelin (Suprefact®, Hoechst,
Germany; 900 mcg/d intranasally) from day 21 of the
incoming cycle. After approximately two weeks, pituitary
suppression was verified (appearance of a menstrual
bleeding, serum estradiol <50 pg/ml, endometrial thickness
<3 mm) before starting COS. In the “short” protocol, the
GnRH-antagonist cetrorelix (Cetrotide®, Merck-Serono,
Germany) was started at a subcutaneous dose of 0.25
mg/d according to a flexible schedule, when at least one
follicle ≥14 mm diameter was observed at ultrasound (US).
IVF cycle management
COS was monitored by serial transvaginal US plus
serum estradiol (E2) measurements performed every sec-
ond day from stimulation day 6–7. The cycle was can-
celled when no more than one follicle ≥11 mm diameter
was seen at US and serum E2 was <80 pg/ml the day of
the first checkpoint. From stimulation day 6–7 onward,
COS continued until at least one dominant follicle
reached 18 mm diameter, with appropriate E2 levels. At
this point, ovulation was triggered by injecting 10,000 IU
of hCG (Gonasi HP®, IBSA, Switzerland) subcutaneously,
and transvaginal US-guided oocyte aspiration (OPU)
was performed approximately 36–37 h later under local
anesthesia (paracervical block). Classical IVF or ICSI
were performed according to clinical indication. After
two days of in vitro culture, embryos were scored ac-
cording to Holte [18] and 1–3 embryos were transferred
in utero using a soft catheter (Sydney, Cook, Australia)
under US guidance. If several good scoring embryos
were obtained, surplus embryos were frozen and kept in
liquid nitrogen for further use. The luteal phase was
supported administering 180 mg/d natural progesterone
(Crinone 8®, Merck-Serono, Germany) for 15 days. Preg-
nancy was assessed by serum hCG assay after 15 days
from embryo transfer (ET) and then confirmed if at least
one gestational sac was visualized at transvaginal US
after two further weeks. Only cases with US confirm-
ation of pregnancy were counted in the calculation of
pregnancy rates, whereas biochemical pregnancies were
not considered.
Statistical analysis
The primary end point of the study was to evaluate the
pregnancy rate per embryo transfer (PR/ET) with fresh
embryos according to the number of retrieved oocytes
and to the type of gonadotropin used (recombinant vs.
urinary). Actually, the following subgroups were evalu-
ated: 1–2, 3–4, 5–6, 7–8, >8 retrieved oocytes; in each
subgroup the PR/ET obtained using rFSH + rLH or
hMG were then compared. The secondary endpoint was
to evaluate the influence of basal day 3 FSH levels,
maternal age and type of pituitary down-regulation on
the primary endpoint. For this reason, results were also
stratified by characteristics as basal circulating FSH level
(<10 or ≥ 10 U/l), age at the time of IVF start (<38 years
or ≥38 years) and adoption of either “long” or “short”
protocol for pituitary down-regulation.
Descriptive data were expressed either as absolute
values, percentages or means as appropriate. Compari-
sons between groups for continuous variables were per-
formed using the two-tailed t-test for unpaired data. The
Chi-square test was used to compare the differences in
PR/ET per number of oocytes in the two Groups of
patients. Multivariate logistic regression analysis was
performed to further evaluate the impact of the type of
medication on the probability of obtaining a pregnancy:
the regression model used age, BMI, smoke habit, and
number of retrieved oocytes as covariates. Significance
was defined as a p value <0.05.
Results
Groups A and B did not significantly differ from any
of the recorded anthropomorphic variables describing
Table 1 Anthropometric and clinical data of all patients. Women
in Group A received r-FSH + r-LH/2:1, those in Group B hMG. Data
are expressed as mean ± SD or as percentage
Group A Group B p
Number of patients 398 450
Age (yrs) 36.7 ± 4.0 36.8 ± 4.1 ns
BMI 22.6 ± 3.6 22.0 ± 3.1 ns
Basal (day 3) FSH (IU/l) 8.1 ± 3.3 8.1 ± 3.2 ns
Antral Follicle Count (AFC) 9.9 ± 6.2 10.3 ± 6.7 ns
Main infertility cause (%) ns
Anovulation 1 2
Endometriosis 11 8
Male 44 51
Tubal 16 13
Unexplained 17 17
Mixed 11 9
Smoke habit (%) 16.3 20.2 ns
Total Gonadotropin dose (IU) 2705 ± 1598 2837 ± 1171 ns
Peak E2 (pg/ml) 2644 ± 1117 2303 ± 990 ns
Retrieved oocytes/patient 6.7 ± 4.2 6.1 ± 4.1 ns
MII oocytes/patient 4.3 ± 2.7 4.2 ± 2.3 ns
Embryo morphological score 6.1 ± 3.6 6.2 ± 3.6 ns
Top scored (>8/10) embryos (%) 21 20 ns
Number of transferred embryos 2.0 ± 0.1 2.0 ± 0.1 ns
Endometrial thickness (mm) 10.8 ± 2.3 10.6 ± 2.2 ns
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patients’ population, suggesting the absence of a selec-
tion bias in the allocation of patients in the two groups
(Table 1). Similarly, the recorded variables concerning
COS were similar in both groups, suggesting a homoge-
neous cycle management regardless of which medication
was used (Table 1).
The overall trend of the clinical PR/ET in the two
study groups, stratified according to the number of re-
trieved oocytes, is summarized in Fig. 1a: as a general
trend, IVF outcome showed a progressive improvement
in parallel with the increase in the number of retrieved
oocytes in both Groups.
Comparing subgroups of patients who had the same
oocyte yield (1–2, 3–4, 5–6, 7–8, or > 8 oocytes retrieved
at OPU), the difference between Group A and B became
progressively more pronounced in parallel with the in-
creasing number of available oocytes (Fig. 1a). Indeed,
the clinical PR/ET of Groups A and B were similar up to
6 retrieved oocytes; with 7–8 oocytes, a non-significant
trend toward better results was observed in Group A;
with more than 8 oocytes available, Group A obtained
a significantly higher success rate (p = 0.038; Fig. 1a).
When comparing the clinical, hormonal and US parame-
ters of patients who obtained more than 8 oocytes in the
two Groups (Table 2), no significant difference was no-
ticed, suggesting once again that the better IVF outcome
in Group A was not due to a patients’ selection bias.
The better performance in Group A was even more
pronounced when only mature (MII) oocytes were
considered: with more than 8 MII oocytes, the PR/
ET in Group A was significantly higher than in
Group B (p = 0.013, Fig. 1b). Interestingly enough, both
in the whole group (Table 1) and in the subgroup of the
most responsive patients (Table 2), no significant differ-
ence in the embryo morphological score, the proportion
of top-scored embryos, and the endometrial thickness
was found, suggesting that subtle factors, not detectable
by morphological methods, could be at the basis of the
observed difference in the clinical PR. The multivariable
logistic regression model confirmed that both the use of
rFSH + rLH and the total number of retrieved oocytes
increased the probability of pregnancy with OR of 1.628
(C.I. 1.163–2.279) and 1.083 (C.I. 1.042–1.126), respect-
ively (Table 3).
Fig. 1 Pregnancy rate per embryo transfer (PR/ET) in subgroups of patients stratified according to the number retrieved oocytes (a) or to the
number of mature (MII) oocytes (b). Pale columns correspond to patients who received rFSH + rLH/2:1 (Group A, n = 398), dark columns to
patients who received hMG (Group B, n = 450). *p = 0.0038; **p = 0.013
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Stratification of the sample according to some baseline
patients’ characteristics showed that the better IVF out-
come observed in Group A for the most responsive
patients was independent from the basal FSH level (this
was observed both when it was >10 U/l and when it was
<10 U/l), from age (it was observed both for women
below 38 years and for those above), and from the type
of down-regulation used (it was observed both in the
long and short protocols) (not shown).
Discussion
Even if FSH alone may be sufficient to obtain follicular
growth in COS, endogenous LH may be so deeply
suppressed by pituitary down-regulation that some LH
activity may be useful to achieve adequate steroidoge-
nesis and develop the capacity of the follicle to ovulate
and luteinize when exposed to hCG [19, 20]. Before
recombinant-LH availability on the market, highly puri-
fied hMG was the only source of exogenous LH activity;
hMG, however, contains a little amount of LH, most of
its LH activity deriving from human chorionic gonado-
tropin (hCG) content rather than from LH itself [21].
Indeed LH and hCG share more than 80 % sequence
homology and bind the same receptor, the luteinizing
hormone-chorionic gonadotropin receptor (LHCGR)
[22, 23]. However, in vitro studies showed that LHCGR
is able to differentiate the LH and hCG action at the
molecular level [24], reflecting the different role of the
two molecules in human physiology: during follicle de-
velopment and first trimester pregnancy, respectively.
Binding of the ligand to LHCGR activates several
intracellular signaling pathways: i) the cyclic AMP-
protein kinase A (cAMP/PKA) pathway, which stimu-
lates steroidogenesis [25] and apoptosis [26] in granulosa
cells; ii) the AKT-pathway, involved in protection from
apoptosis [24], and iii) the ERK1/2-pathway, involved in
resumption of oocyte meiosis and in proliferation, differ-
entiation and survival of granulosa cells [27]. So far,
these pathways play a crucial role in the final stages of
maturation of human oocytes and follicles. Cyclic AMP-
protein kinase A (cAMP/PKA) pathway is more rapidly
activated after LH than after hCG exposure, but the ef-
fect of hCG is more persistent, due to its longer half-life
(60–120 min for LH vs. several hours for hCG) [28, 29]
generating similar steroidogenetic activity. In contrast,
AKT- and ERK1/2-pathways are significantly different
after LH o rhCG exposure, showing a more favorable
effect of LH as anti-apoptotic and oocyte maturation
modulator [24]. The long half-life of hCG, moreover, is
able to exert a down-regulation and internalization of
the LHCGR, that was described in cultured LH-sensitive
cells after repeated, low dose hCG administration [30],
and in the long run reduces the sensitivity of the recep-
tor in the target tissues.
To date, very limited clinical data have been generated
comparing the LH activity of rLH vs. that of the hCG
contained in hMG in patients undergoing IVF. Hormo-
nal profiles in serum and follicular fluid obtained using
the association rFSH + rLH during COS were found to
be similar to those obtained with hMG, showing that
their respective steroidogenetic activity at the follicular
level was comparable [31]. In a randomized prospective
study including a small number of FSH-stimulated pa-
tients, normo-gonadotropic women older than 35 obtained
Table 2 Anthropometric and clinical data of patients obtaining
more than 8 oocytes at ovum pick-up. Women in Group A
received r-FSH + r-LH/2:1, those in Group B hMG. Data are
expressed as mean ± SD or as percentage
Group A Group B p
Number of patients 101 109
Age (yrs) 36.2 ± 4.3 35.7 ± 4.5 ns
Basal (day 3) FSH (IU/l) 7.1 ± 2.5 7.2 ± 2.8 ns
BMI 22.7 ± 3.9 22.3 ± 2.9 ns
Main infertility cause (%) ns
Anovulation 0 0.9 %
Endometriosis 8.9 8.3
Male 43.6 43.1
Tubal 11.9 18.3
Unexplained 24.7 23.8
Mixed 10.9 5.5
Smokehabit (%) 14.8 20.2 ns
Total Gonadotropin dose (IU) 2453 ± 1539 2801 ± 1117 ns
Peak E2 (pg/ml) 2924 ± 1175 2649 ± 964 ns
Retrieved oocytes/patient 12.4 ± 3.6 11.9 ± 3.3 ns
MII oocytes/patient 9.2 ± 2.4 9.1 ± 2.3 ns
Embryo morphological score 7.1 ± 2.8 6.9 ± 3.0 ns
Top scored (>8/10) embryos (%) 28 25 ns
Number of transferred embryos 2.3 ± 0.7 2.4 ± 0.7 ns
Endometrial thickness (mm) 10.6 ± 2.5 10.8 ± 2.2 ns
Table 3 Odd ratio estimates according to the multivariable
logistic regression analysis. The analysis was used to test the
impact of the type of medication used in COS (rFSH + rLH or
hMG) on the likelihood of obtaining a pregnancy, using age,
BMI, smoke habit and number of retrieved oocytes as covariates.
Variables with OR > 1 and 95 % confidence limits both above 1
significantly affect the final outcome (pregnancy)
Odd ratio 95 % confidence limits
Age 0.901 0.863 0.940
BMI 0.978 0.929 1.029
Smoke habit 0.944 0.564 1.581
Type of medication used in COS 1.628 1.163 2.279
Number of retrieved oocytes 1.083 1.042 1.126
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a higher number of preovulatory follicles and of mature
oocytes if supplemented with rLH vs. hMG [32]. Another
small, prospective pilot study on 122 patients undergoing
IVF reported comparable outcome with rFSH + rLH vs.
hMG in terms of embryo quality, pregnancy rate (PR), and
implantation rate (IR) [33]. Results from the German IVF
Registry, including more than 4,000 cycles, showed that
oocyte yield, PR and IR were significantly higher in
patients treated with the combination of rFSH + rLH
compared to women treated either with rFSH + hMG or
hMG alone [34].
Some recent studies, including a huge retrospective
analysis on 400,135 IVF cycles [35] indicate that IVF
outcome improves in parallel with increasing oocyte
yield and the best chance of live birth with fresh embryo
transfer is obtained with a number of retrieved eggs
around 15 [35–37]. It is also well known that recombin-
ant gonadotropins are able to induce the retrieval of
more oocytes than hMG [6, 7], but none of the studies
showing a relationship between IVF outcome and oocyte
yield considered which medication was used for COS.
In the present study, we applied an original approach
comparing the clinical effectiveness of recombinant go-
nadotropins vs. hMG, stratifying a rather large number
of IVF patients with homogeneous characteristics ac-
cording to the number of retrieved oocytes. As both
treatments under investigation were able to generate a
similar number of oocytes, we were able to compare
even subgroups having the same oocyte yield (1–2, 3–4,
5–6, 7–8, and more than 8), but treated with different
medications. This is the first study, to our knowledge,
that uses this approach to compare different COS regi-
mens in IVF patients.
Our observation confirmed the importance of oocyte
yield for a successful IVF, as a positive trend toward
higher PR was observed in parallel with the number of
retrieved oocytes and of mature oocytes. Also, the multi-
variable logistic regression analysis identified the number
of retrieved oocytes as a variable significantly and inde-
pendently affecting the probability of pregnancy (OR
1.083). It was observed, however, that the type of medi-
cation used for COS played a role in determining IVF
outcome: in fact, a similar success rate with recombinant
gonadotropins or hMG was achieved when the number
of available oocytes was 1–6, a non-significantly higher
pregnancy rate using rFSH + rLH with 7–8 oocytes and
finally a significantly higher pregnancy rate with recom-
binant gonadotropins when more than 8 oocytes were
retrieved at OPU. This finding was not justified by
any clinical differences between the two groups, but
depended, apparently, on the type of gonadotropin used.
Also, the multivariable logistic regression analysis
showed that the type of medication used in COS signifi-
cantly and independently affected the probability of
pregnancy, with a highly significant OR of 1.628 in favor
of recombinant gonadotropins. Interestingly enough, it
was recently reported that recombinant gonadotropins
lead to a better IVF outcome than hMG in patients hav-
ing an AFC above six [38].
The reason(s) why recombinant gonadotropins may be
able to lead to a better IVF outcome than hMG in pa-
tients with good ovarian responsiveness, despite an even
number of oocytes, is difficult to determine. As a matter
of fact, when comparing Group A to Group B no differ-
ence in the morphology of the oocytes and of the
derived embryos, nor in endometrial thickness was ob-
served; we can thus speculate that the observed results
could be due to subtle factors, not detectable when
studying embryo morphology or endometrial US appear-
ance. The embryo morphological score that we used [18]
was proven to be quite precisely related to embryo im-
plantation potential, but still it could be inappropriate to
detect subtle differences in embryo competence, in turn
possibly derived from oocyte quality. We performed em-
bryo transfer on day 2 or 3, so unfortunately the blasto-
cyst development rate and the blastocyst morphology
could not be estimated in our patients. As for endomet-
rial quality, the gene and protein expression in endomet-
rial cells was reported to differ in hMG-treated and
rLH-treated subjects [39, 40], and a precocious or pro-
longed hCG exposure (as when hMG is used) was ob-
served to worsen endometrial receptivity in baboons
[41], possibly for the down-regulatory effect of hCG on
the LHCGR [30, 40]. Specifically, the existence of a 2-d
delay in the activation/repression of two clusters of
genes in endometrial cells was demonstrated, respect-
ively, on day hCG + 7 vs. LH + 7; this different gene
regulation could potentially affect the window of im-
plantation in the endometrium [42], as LHCGR expres-
sion affects uterine receptivity [43]. Further, hCG was
also reported to induce pro-apoptotic molecules in
endometrial cells [44], and it was shown that the out-
come of thawed embryo transfer in spontaneous cycles
was better with endogenous LH surge than after a single
hCG bolus [45].
In conclusion, we performed herein an original evalu-
ation of the real-life data generated from routine clinical
activity in order to assess the efficacy of different medi-
cations for COS. Studying several hundreds of IVF pa-
tients with homogeneous characteristics and classified as
poor or normal responders to gonadotropins, we ob-
served that hMG and the rFSH + rLH/2:1 association
were similarly effective in generating a clinical pregnancy
when less than 8 oocytes were retrieved, but recombin-
ant gonadotropins were significantly more effective
when 8 or more oocytes were available. These findings
cannot be explained by a selection bias, by a difference
in patients’ characteristics or by an uneven number of
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retrieved oocytes; they are likely linked to the type of
gonadotropin used in COS, and depend on some subtle,
different effect of LH and hCG on oocyte and/or endo-
metrial characteristics. The more favorable clinical out-
come we observed using recombinant gonadotropins in
normal responders, in spite of a similar oocyte yield,
could be further investigated in a large, prospective clin-
ical trial; in parallel, a targeted basic research could be
performed in order to clarify the subtle mechanisms of
action of rLH and hCG at the follicular and endometrial
level.
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